Aktualisierung der „Living Guideline“ Colitis ulcerosa 2022
Author:
Affiliation:
1. Klinikum Lüneburg, Klinik für Allgemeine Innere Medizin und Gastroenterologie, Deutschland
2. Medizinische Klinik 1, Agaplesion Markus Krankenhaus Frankfurt/Main, Frankfurt am Main, Deutschland
Publisher
Georg Thieme Verlag KG
Subject
Gastroenterology
Link
http://www.thieme-connect.de/products/ejournals/pdf/10.1055/a-1975-0509.pdf
Reference8 articles.
1. [Updated S3-Guideline Colitis ulcerosa. German Society for Digestive and Metabolic Diseases (DGVS) – AWMF Registry 021/009];Z Gastroenterol,2018
2. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial;B G Feagan;Lancet,2021
3. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis;W J Sandborn;N Engl J Med,2021
4. Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study;W J Sandborn;J Crohns Colitis,2021
5. Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial;B A Cree;Mult Scler,2022
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3